Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma

Table 1 Efficacy outcomes in the phase III REFLECT trial[11]

	Lenvatinib (n = 478)	Sorafenib (n = 476)	HR (95%CI)	P value
Median OS	13.6 mo	12.3 mo	0.92 (0.79-1.06)
Median PFS	7.4 mo	3.7 mo	0.66 (0.57-0.77)	P < 0.0001
Median TTP	8.9 mo	3.7 mo	0.63 (0.53-0.73)	P < 0.0001
ORR	24.1%	9.2%	OR (95%CI): 3.13 (2.15-4.56)	P < 0.0001
DCR	75.5%	60.5%	-

OS: Overall survival; PFS: Progression-free survival; TTP: Time to progression; ORR: Overall response rate; DCR: Disease control rate; HR: Hazard ratio; OR: Odds ratio; CI: Confidence interval.